Literature DB >> 30474827

Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series.

Rajiv Mehta1, Mayank Kabrawala2, Subhash Nandwani2, Parika Kalra2, Chintan Patel2, Pankaj Desai3, Krishna Parekh4.   

Abstract

Experimental studies demonstrated that fecal microbiota transplant (FMT) may reverse intestinal microbial dysbiosis. In this retrospective case series, we share our experience of treating recurrent overt hepatic encephalopathy (HE) with single FMT treatment. A total of 10 patients, age ranged from 25 to 65 years, were treated with single FMT through colonoscopy using fecal material received from rigorously screened patient-identified donors. There was sustained clinical response with single FMT treatment in 6 patients at post-treatment week 20. Arterial ammonia concentration decreased considerably (96 [87.25-117.75] vs. 74 [70-82]; p = 0.024) at post-treatment week 20. Moreover, there was statistically significant decrease in Child-Turcotte-Pugh (CTP) score (9.5 [9-10.75] vs. 8 [7-8]; p = 0.005) and model for end-stage liver disease (MELD) score (18 [16.25-19] vs. 15 [14-16]; p = 0.008). Four patients experienced six adverse-events. Overt HE and re-hospitalization were observed in 3 and 2 patients, respectively. One patient (who also experienced overt HE) died within 2 months of the index procedure.

Entities:  

Keywords:  Cirrhosis; Dysbiosis; Fecal microbiota transplant; Hepatic encephalopathy

Mesh:

Year:  2018        PMID: 30474827     DOI: 10.1007/s12664-018-0906-1

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  9 in total

1.  Just another crappy commentary: the future of fecal microbiota transplantation.

Authors:  James T Rosenbaum
Journal:  Expert Rev Clin Immunol       Date:  2019-10-08       Impact factor: 4.473

Review 2.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

Review 3.  Gut Barrier and Microbiota in Cirrhosis.

Authors:  Cyriac A Philips; Philip Augustine
Journal:  J Clin Exp Hepatol       Date:  2021-09-03

Review 4.  A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Hepatic Encephalopathy and Clostridioides difficile Infection in Patients With Cirrhosis.

Authors:  Kyaw Min Tun; Annie S Hong; Kavita Batra; Yassin Naga; Gordon Ohning
Journal:  Cureus       Date:  2022-05-31

Review 5.  Evidence-based approach to management of hepatic encephalopathy in adults.

Authors:  Gilles Jadd Hoilat; Fathima Keshia Suhail; Talal Adhami; Savio John
Journal:  World J Hepatol       Date:  2022-04-27

6.  New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.

Authors:  Phillipp Hartmann; Bernd Schnabl
Journal:  Semin Liver Dis       Date:  2021-01-14       Impact factor: 6.115

Review 7.  The microbiota in cirrhosis and its role in hepatic decompensation.

Authors:  Jonel Trebicka; Jane Macnaughtan; Bernd Schnabl; Debbie L Shawcross; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 8.  Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment.

Authors:  Ramzi Hassouneh; Jasmohan S Bajaj
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

Review 9.  Fecal Microbiota Transplantation in Decompensated Cirrhosis: A Systematic Review on Safety and Efficacy.

Authors:  Annie S Hong; Kyaw Min Tun; Jenny M Hong; Kavita Batra; Gordon Ohning
Journal:  Antibiotics (Basel)       Date:  2022-06-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.